Here, we discuss how to improve adherence to endocrine therapy in women with HR-positive breast cancer, as well as the side effects and the reasons for discontinuation.
Julia P. Brockway, MD
Advertisement
Articles by Julia P. Brockway, MD
Advertisement
Latest Updated Articles
- Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast Cancer
Published: May 15th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC
2
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer
3
FDA Grants Regular Approval to Rucaparib in Metastatic CRPC
4
Pelareorep Exhibits Activity in Second-Line KRAS-Mutated Metastatic CRC
5